Details for New Drug Application (NDA): 206544
✉ Email this page to a colleague
NDA 206544 describes MORPHABOND ER, which is a drug marketed by Ohemo Life and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the MORPHABOND ER profile page.
The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
Summary for 206544
| Tradename: | MORPHABOND ER |
| Applicant: | Ohemo Life |
| Ingredient: | morphine sulfate |
| Patents: | 2 |
Medical Subject Heading (MeSH) Categories for 206544
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 15MG | ||||
| Approval Date: | Oct 2, 2015 | TE: | RLD: | Yes | |||||
| Patent: | 10,314,788 | Patent Expiration: | Aug 12, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | 7,955,619 | Patent Expiration: | Aug 12, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 30MG | ||||
| Approval Date: | Oct 2, 2015 | TE: | RLD: | Yes | |||||
| Patent: | 10,314,788 | Patent Expiration: | Aug 12, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
